No evidence for a higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta- regression. [Abstract PS-160.]

Waziry R, Hajarizadeh B, Grebely J, Dore GJ. No evidence for a higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta- regression. [Abstract PS-160.]. In EASL International Liver Congress. Amsterdam, April 19-23EASL International Liver Congress. Amsterdam, April 19-23. 2017.

Publication Type:

Conference Paper

Source:

EASL International Liver Congress. Amsterdam, April 19-23EASL International Liver Congress. Amsterdam, April 19-23 (2017)
Top